Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Tailin Bioengineering Co's FCF Margin % or its related term are showing as below:
SZSE:300813'
s FCF Margin % Range Over the Past 10 Years
Min: -64.59 Med: 2.65 Max: 49.55
Current: 5.99
During the past 10 years, the highest FCF Margin % of Zhejiang Tailin Bioengineering Co was 49.55%. The lowest was -64.59%. And the median was 2.65%.
SZSE:300813's FCF Margin % is ranked better than 62.42% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 0.19
vs SZSE:300813: 5.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Tailin Bioengineering Co FCF Margin % Chart
SZSE:300813 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Zhejiang Tailin Bioengineering Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Tailin Bioengineering Co FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Tailin Bioengineering Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Tailin Bioengineering Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Tailin Bioengineering Co (SZSE:300813) has a FCF Margin % of 9.37% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhejiang Tailin Bioengineering Co and its competitors. This is 254% above median its historical median of 2.65. According to the industry distribution chart, Zhejiang Tailin Bioengineering Co ranks #310 out of 825 companies in the Medical Devices & Instruments industry, placing it in the top 37.6%.
Is Zhejiang Tailin Bioengineering Co's FCF Margin % too high?
Zhejiang Tailin Bioengineering Co's current FCF Margin % of 9.37% is 254% above median its 10-year median of 2.65. The Medical Devices & Instruments industry median FCF Margin % is 0.19. Zhejiang Tailin Bioengineering Co's value of 9.37% is 4831.6% above this industry median. Based on the distribution chart, Zhejiang Tailin Bioengineering Co ranks #310 out of 825 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zhejiang Tailin Bioengineering Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Tailin Bioengineering Co's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Tailin Bioengineering Co ranks #310 out of 825 companies for FCF Margin %. This puts Zhejiang Tailin Bioengineering Co in the upper half of its industry. The industry median FCF Margin % is 0.19. Zhejiang Tailin Bioengineering Co's value of 9.37% is 4831.6% above this benchmark. While the company's 10-year median is 2.65 vs. the industry median of 0.19, Zhejiang Tailin Bioengineering Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
The median FCF Margin % among Medical Devices & Instruments companies is 0.19, based on 825 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Tailin Bioengineering Co's current FCF Margin % of 9.37% is 4831.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhejiang Tailin Bioengineering Co and its competitors. For the Medical Devices & Instruments industry, the median FCF Margin % is 0.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Tailin Bioengineering Co's current FCF Margin % is 9.37%, which is 254% above median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Tailin Bioengineering Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Tailin Bioengineering Co (SZSE:300813) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.96, compared to a current price of ¥19.85 — trading 5.3% below its estimated fair value. The current FCF Margin % is 9.37%, which is 254% above median its 10-year median of 2.65 and 4831.6% above the Medical Devices & Instruments industry median of 0.19. Zhejiang Tailin Bioengineering Co's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zhejiang Tailin Bioengineering Co (SZSE:300813), the current FCF Margin % is 9.37% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Tailin Bioengineering Co (SZSE:300813) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Tailin Bioengineering Co stock appears to be undervalued.
The current stock price of ¥19.85 is trading 5.3% below its estimated GF Value™ of ¥20.96.
GuruFocus considers Zhejiang Tailin Bioengineering Co to be Fairly Valued.
Key valuation signals for SZSE:300813:
FCF Margin %: 9.37% (254% above median its 10-year median of 2.65)
GF Value™: ¥20.96 vs. price of ¥19.85 (5.3% below fair value)
Industry Position: 4831.6% above the Medical Devices & Instruments median (#310 of 825)
No single metric tells the full story. See the SZSE:300813 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300813 has been successfully added to your 
